Logo image of PRFX

PAINREFORM LTD (PRFX) Stock Fundamental Analysis

NASDAQ:PRFX - Nasdaq - IL0011651580 - Common Stock

2.99  -0.03 (-0.99%)

Premarket: 2.98 -0.01 (-0.33%)

Fundamental Rating

1

Overall PRFX gets a fundamental rating of 1 out of 10. We evaluated PRFX against 195 industry peers in the Pharmaceuticals industry. PRFX has a bad profitability rating. Also its financial health evaluation is rather negative. PRFX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PRFX has reported negative net income.
PRFX had a negative operating cash flow in the past year.
PRFX had negative earnings in each of the past 5 years.
In the past 5 years PRFX always reported negative operating cash flow.
PRFX Yearly Net Income VS EBIT VS OCF VS FCFPRFX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -2M -4M -6M -8M

1.2 Ratios

PRFX has a worse Return On Assets (-568.81%) than 96.77% of its industry peers.
Industry RankSector Rank
ROA -568.81%
ROE N/A
ROIC N/A
ROA(3y)-67.8%
ROA(5y)-86.78%
ROE(3y)-82.98%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PRFX Yearly ROA, ROE, ROICPRFX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRFX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRFX Yearly Profit, Operating, Gross MarginsPRFX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

PRFX has less shares outstanding than it did 1 year ago.
PRFX has less shares outstanding than it did 5 years ago.
PRFX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PRFX Yearly Shares OutstandingPRFX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K 1M
PRFX Yearly Total Debt VS Total AssetsPRFX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

PRFX has an Altman-Z score of -44.00. This is a bad value and indicates that PRFX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -44.00, PRFX is doing worse than 93.01% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -44
ROIC/WACCN/A
WACCN/A
PRFX Yearly LT Debt VS Equity VS FCFPRFX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M 15M

2.3 Liquidity

PRFX has a Current Ratio of 0.61. This is a bad value and indicates that PRFX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.61, PRFX is doing worse than 96.24% of the companies in the same industry.
A Quick Ratio of 0.61 indicates that PRFX may have some problems paying its short term obligations.
PRFX has a worse Quick ratio (0.61) than 91.94% of its industry peers.
Industry RankSector Rank
Current Ratio 0.61
Quick Ratio 0.61
PRFX Yearly Current Assets VS Current LiabilitesPRFX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

PRFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1758.81%.
EPS 1Y (TTM)-1758.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1336.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PRFX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.27% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y51.55%
EPS Next 2Y30.54%
EPS Next 3Y21.27%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRFX Yearly Revenue VS EstimatesPRFX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
PRFX Yearly EPS VS EstimatesPRFX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -100 -200 -300 -400

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PRFX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRFX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRFX Price Earnings VS Forward Price EarningsPRFX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRFX Per share dataPRFX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -20 -40 -60 -80 -100

4.3 Compensation for Growth

A more expensive valuation may be justified as PRFX's earnings are expected to grow with 21.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.54%
EPS Next 3Y21.27%

More info and screens

0

5. Dividend

5.1 Amount

PRFX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PAINREFORM LTD

NASDAQ:PRFX (1/21/2025, 8:21:35 PM)

Premarket: 2.98 -0.01 (-0.33%)

2.99

-0.03 (-0.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-22 2024-11-22/amc
Earnings (Next)N/A N/A
Inst Owners4.31%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.60M
Analysts43.33
Price TargetN/A
Short Float %6.58%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-39.45%
Min EPS beat(2)-67.8%
Max EPS beat(2)-11.11%
EPS beat(4)1
Avg EPS beat(4)-12.48%
Min EPS beat(4)-104.63%
Max EPS beat(4)133.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-300%
EPS NY rev (1m)0%
EPS NY rev (3m)-2300%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-123.78
EYN/A
EPS(NY)-49.2
Fwd EYN/A
FCF(TTM)-13.09
FCFYN/A
OCF(TTM)-13.06
OCFYN/A
SpS0
BVpS-2.35
TBVpS-2.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -568.81%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-67.8%
ROA(5y)-86.78%
ROE(3y)-82.98%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 161.54%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.61
Quick Ratio 0.61
Altman-Z -44
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)203.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1758.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1336.27%
EPS Next Y51.55%
EPS Next 2Y30.54%
EPS Next 3Y21.27%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-77.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-94.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.91%
OCF growth 3YN/A
OCF growth 5YN/A